Released Aug 10, 2023, after the close
10-Q filed Aug 10, 2023, 41 days after period end · 0001390478-23-000019
Q2 2023 · 10-Q
Revenue$0.00$0.00 — vs Q2 2022no prior Q1 2023 on file
Net Income-$8.84M-$8.84M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.31-$0.31 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$9,050,000N/M
Operating Cash Flowderived-$7,566,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $1.90M | $0.00 |
| Net Income | -$8.84M | -$8.41M | -$4.61M | -$4.43M |
| EPS Diluted | -$0.31 | -$0.41 | -$0.30 | -$0.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR